- Home
- LIXT vs INM Comparison
LIXT vs INM Comparison
Compare LIXT & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- INM
- Stock Information
- Founded
- LIXT 2005
- INM 1981
- Country
- LIXT United States
- INM Canada
- Employees
- LIXT N/A
- INM N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- INM Health Care
- Exchange
- LIXT Nasdaq
- INM Nasdaq
- Market Cap
- LIXT 3.0M
- INM 3.2M
- IPO Year
- LIXT N/A
- INM N/A
- Fundamental
- Price
- LIXT $0.74
- INM $3.33
- Analyst Decision
- LIXT
- INM
- Analyst Count
- LIXT 0
- INM 0
- Target Price
- LIXT N/A
- INM N/A
- AVG Volume (30 Days)
- LIXT 82.2K
- INM 9.5M
- Earning Date
- LIXT 08-07-2025
- INM 05-12-2025
- Dividend Yield
- LIXT N/A
- INM N/A
- EPS Growth
- LIXT N/A
- INM N/A
- EPS
- LIXT N/A
- INM N/A
- Revenue
- LIXT N/A
- INM $4,920,990.00
- Revenue This Year
- LIXT N/A
- INM N/A
- Revenue Next Year
- LIXT N/A
- INM N/A
- P/E Ratio
- LIXT N/A
- INM N/A
- Revenue Growth
- LIXT N/A
- INM N/A
- 52 Week Low
- LIXT $0.64
- INM $1.72
- 52 Week High
- LIXT $3.00
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- LIXT 30.79
- INM 59.24
- Support Level
- LIXT $0.64
- INM $2.26
- Resistance Level
- LIXT $0.93
- INM $5.50
- Average True Range (ATR)
- LIXT 0.13
- INM 0.40
- MACD
- LIXT -0.05
- INM 0.11
- Stochastic Oscillator
- LIXT 16.99
- INM 37.04
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.